Dr. Lerner on OLYMPUS Jelmyto trial: “We've learned a lot of lessons”

“The message is to please consider kidney preservation for these patients with TA low-grade disease,” says Seth P. Lerner, MD.

In this video, Seth P. Lerner, MD, discusses why the findings of the OLYMPUS trial will change the way that clinicians treat patients with upper tract urothelial carcinoma. Lerner is a professor in the Scott Department of Urology and Beth and Dave Swalm Chair in urologic oncology at the Baylor College of Medicine Medical Center in Houston, Texas.

Related Content:

Bladder CancerUTv
Study shows low public awareness of smoking as a risk factor for bladder cancer
FDA approval sought for N-803 in NMIBC
Nivolumab/ipilimumab falls short as frontline treatment in advanced urothelial carcinoma